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Chronic activation of CD8 T-cell compartment is critical
during HCV-HIV-1 coinfection. The objective of this
study was to evaluate the impact of pegylated-interferon
(PEG-IFN) in combination with ribavirin (RBV) on
immune activation in HCV-HIV-coinfected patients.
T cell phenotype (CD8+CD38+,CD8+DR+) was quan-
tified using flow cytometry analysis,. Measurements
were performed at day one of treatment (Baseline, BL),
then at week (W)12,W24,W48 and W24 post-treatment.
HVC viral load was measured using a PCR (COBAS
TaqMan 48; Roche), exhibiting a limit of detection at12
IU/ml. Statistical analysis was performed with SPSS 17.0.
11 pts (64% of males; median age 47.4 [45.1-51]) with
a median follow up for HCV infection of 14.7y [11.7;
19.1]) were evaluated. All were treated for HIV infection
(PI- based regimen: 63.6%) with an HIV-VL < 40copies/
ml. Median CD4 and CD8 T cells count at BL was 886/
mm3 [671; 1008] and 825/mm3 [530; 1843], respec-
tively. HCV genotype was 1 for 63.6%, 3 in 27.3% and 4
in one pt. HCV VL at BL was 5.9 [4.6; 6.7] (log UI/ml).
Up to now, 2 pts stopped HCV treatment at W2 and
W4, 9 pts have reached W24, and 5 of them are
between W24 and W48. The results at W12 and W24
are presented in the table. We observed a significant
decrease of the number of circulating total lymphocytes
and CD4T cells in absolute value (p=0.008), but a signif-
icant increase in the percentage of CD4+ T-cells and a
significant decrease in the percentage of CD8+ T cells
at W24. HCV VL was negative for all of them.
These preliminary results show that the immune system
hyperactivation driving by HCV disease can be reduced
with a control of HCV replication. However, we observed
a discrepancy in the evolution of CD8+CD38+ and CD8
+DR+ expression at W12 which remains at W24.These
results have to be confirmed with the next measurement
performed at W48 and W24 post treatment.
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Table 1
BL W12 p W24 p
CD4+ T Cell (%) 27.0 [24.5; 37.1] 37.5 [26.8; 46.0] 0.008 43.0 [30.5; 47.3] 0.011
CD8+ T Cell (%) 46.0 [30.4; 51.0] 43.2 [25.9; 49.7] 0.110 37.4 [26.5; 46.9] 0.028
DR+CD8+ T Cell (%) 11.0 [6.4; 19.5] 5.2 [2.8; 9.9] 0.017 2.4 [1.4; 7.4] 0.008
CD38+CD8+ T Cell (%) 14.7 [6.8; 21.5] 43.2 [28.9; 48.9] 0.008 36.2 [15.7; 47.1] 0.015
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